0000000000135163

AUTHOR

I Benet

showing 15 related works from this author

Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absenc…

2011

Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection

MaleTransplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesHematologyPolymerase Chain ReactionAdenoviridaeAdenovirus Infections HumanTransplantationsurgical procedures operativeUnrelated DonorImmunologyHumansMedicineFemaleStem cellbusinessBone Marrow Transplantation
researchProduct

Chromosome 5 abnormalities in acute lymphoblastic leukemia

1991

Abstract We report two cases of acute lymphoblastic leukemia with involvement of chromosome 5. One of them showed a del(5)(q13q33) in a 5-year-old boy who had previously received antineoplastic chemotherapy for an L1-ALL that had been diagnosed nine months before. The other one showed a t(5;7)(q12–13;q36) together with a t(8;14)(q24;q32) and a der(1) in a 66-year-old man with an L3-ALL. Both chromosome 5 aberrations are interpreted as evolutionary events. In the first case, it was secondary to chemotherapy treatment; in the second, an evolutionary chromosome rearrangement, considering the translocation between chromosomes 8 and 14 as the primary cytogenetic event.

MaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentLymphoblastic LeukemiaChromosome DisordersChromosomal translocationChromosomal rearrangementBiologyAcute lymphocytic leukemiaAntineoplastic chemotherapyGeneticsmedicineHumansMolecular BiologyChromosome AberrationsChemotherapyCytogeneticsChromosomePrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseChromosome BandingChild PreschoolKaryotypingImmunologyCancer researchChromosomes Human Pair 5Cancer Genetics and Cytogenetics
researchProduct

Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome

2003

Background: High serum levels of soluble intercellular adhesion molecule-1(s-ICAM-1/s-CD54) have been associated with adverse clinical features and poor outcome in chronic lymphocytic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma, but their value in the different subtypes of non-Hodgkin’s lymphoma has not been well addressed. Patients and methods: Our aim was to study the serum levels of s-ICAM-1 in diffuse large B-cell lymphoma (DLBCL) and to correlate them with clinical characteristics and outcome. We analyzed the serum levels of s-ICAM-1 in a series of 55 patients with DLBCL diagnosed in a single institution. s-ICAM-1 levels were quantified by an immunoenzymatic assay. Median ag…

AdultMalemedicine.medical_specialtyPathologyLymphoma B-CellChronic lymphocytic leukemiaGastroenterologyImmunoenzyme TechniquesInternational Prognostic IndexRisk Factorshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansSurvival analysisAgedAged 80 and overL-Lactate DehydrogenaseBeta-2 microglobulinbusiness.industryLymphoma Non-HodgkinLarge-cell lymphomaHematologyMiddle AgedIntercellular Adhesion Molecule-1Prognosismedicine.diseaseSurvival AnalysisLymphomaTreatment OutcomeOncologyB symptomsCase-Control StudiesLymphatic MetastasisDisease ProgressionFemaleLymphoma Large B-Cell Diffusemedicine.symptombusinessDiffuse large B-cell lymphomaAnnals of Oncology
researchProduct

Ex vivo expansion of umbilical cord blood (UCB) CD34+ cells alters the expression and function of α4β1 and α5β1 integrins

2001

We have investigated the influence of ex vivo expansion of human CD34+ cord blood cells on the expression and function of adhesion molecules involved in the homing and engraftment of haematopoietic progenitors. Ex vivo expansion of umbilical cord blood CD34+ cells for 6 d in the presence of interleukin 3 (IL-3), IL-6 and stem cell factor (SCF) or IL-11, SCF and Flt-3L resulted in increased expression of α4, α5, β1, αΜM and β2 integrins. However, a significant decrease in the adhesion of progenitor cells to fibronectin was observed after the ex vivo culture (adhesion of granulocyte-macrophage colony-forming units (CFU-GM) was 22 ± 4% in fresh cells versus 5 ± 2% and 2 ± 2% in each combinatio…

HaematopoiesisCell adhesion moleculeCord bloodImmunologyCD34HematologyBiologyProgenitor cellStem cellMolecular biologyEx vivoInterleukin 3British Journal of Haematology
researchProduct

Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breas…

2001

The aim of this study was to determine whether the detection of CTC in the apheresis product contribute significantly to treatment failure of patients with high-risk breast carcinoma treated with high-dose chemotherapy (HDC) and stem cell transplantation (SCT). Patients were with stage II and III adenocarcinoma of the breast with > or = 10 axillary lymph nodes affected after primary surgery (> or = 10 N+) who had received HDC with SCT. We analyzed retrospectively the presence of CTC as assessed by immunocytochemistry (ICC) in the apheresis products obtained after standard adjuvant chemotherapy. We compared the clinical outcome of patients who received HDC and SCT with or without CTC-positiv…

Adultmedicine.medical_specialtyAxillary lymph nodesmedicine.medical_treatmentBreast NeoplasmsCell SeparationGastroenterologyBreast cancerRecurrenceRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansTreatment FailureSurvival rateRetrospective StudiesAnalysis of VarianceTransplantationChemotherapybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedPrognosismedicine.diseaseCombined Modality TherapyImmunohistochemistrySurgerySurvival RateTransplantationApheresismedicine.anatomical_structureBlood Component RemovalNeoplastic Stem CellsAdenocarcinomaFemaleBreast carcinomabusinessBone Marrow Transplantation
researchProduct

Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8+ and CD4+ T-cell responses affording protection from CMV DNAemia following allogeneic hematopo…

2011

Threshold levels of CMV-specific T-cell populations presumably affording protection from active CMV infection in allo-SCT recipients have been proposed, but lack extensive validation. We quantified CMV pp65 and immediate-early 1-specific IFN-γ CD8(+) and CD4(+) T cell responses at days +30, +60 and +90 after transplantation in 133 patients, and established cutoff cell levels protecting from CMV DNAemia within the first 120 days after transplantation. No patients showing IFN-γ CD8(+) or IFN-γ CD4(+) T-cell counts1.0 and1.2 cells/μL, respectively, developed a subsequent episode of CMV DNAemia. Initial or recurrent episodes of CMV DNAemia occurred in the face of IFN-γ T-cell levels below defin…

AdultCD4-Positive T-LymphocytesMaleAdolescentGlobulinT cellCytomegalovirusCD8-Positive T-LymphocytesImmediate-Early ProteinsViral Matrix ProteinsInterferon-gammamedicineHumansTransplantation HomologousAgedTransplantationCd4 t cellbiologyUmbilical Cord Blood Transplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesHematologyCmv dnaemiaMiddle AgedPhosphoproteinsTransplantationHaematopoiesismedicine.anatomical_structureCytomegalovirus InfectionsDNA ViralImmunologybiology.proteinFemaleVirus ActivationbusinessCD8Bone Marrow Transplantation
researchProduct

Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia

2004

In B-cell chronic lymphocytic leukemia (B-CLL), somatic mutation of IgVH genes defines a subgroup with favorable prognosis, whereas the absence of IgVH mutations is correlated with a worse outcome. Mutations of the BCL-6 gene are also observed in a subset of B-CLL, but the clinical significance of this molecular alteration remains uncertain. We examined the distribution of IgVH and BCL-6 gene mutations in 95 well-characterized patients with Binet stage A B-CLL, and correlated them with clinical, laboratory, cytogenetic findings and disease progression. Mutations of the BCL-6 gene were observed only in cases harboring mutated IgVH. Unexpectedly, coexistence of IgVH and BCL-6 mutations was co…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyChronic lymphocytic leukemiaImmunoglobulin Variable RegionLocus (genetics)BiologyGene mutationDisease-Free SurvivalGermline mutationProto-Oncogene ProteinsInternal medicinemedicineHumansB-cell chronic lymphocytic leukemiaClinical significanceProspective StudiesGeneAgedAged 80 and overHematologyChromosomes Human Pair 11HematologyMiddle AgedPrognosismedicine.diseaseLeukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsOncologyMutationImmunologyProto-Oncogene Proteins c-bcl-6FemaleChromosome DeletionChromosomes Human Pair 17Follow-Up StudiesTranscription FactorsLeukemia
researchProduct

Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocat…

1998

Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12)

Geneticscongenital hereditary and neonatal diseases and abnormalitiesCancer ResearchAlpha interferonChromosomal translocationHematologyBiologymedicine.diseaseCytogenetic ResponseLymphomaOncologyhemic and lymphatic diseasesCancer researchmedicineEosinophiliaT-cell lymphomamedicine.symptomLeukemia
researchProduct

Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of th…

2000

We determined prospectively the incidence of chromosomal abnormalities in patients with high-risk breast cancer (HRBC) after high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT), and correlated the cytogenetic abnormalities with the development of post-transplant myelodysplastic syndrome or acute myeloid leukemia (MDS/AML). From 1990 to 1999, 229 women with HRBC underwent ASCT. Cytogenetic analysis of bone marrow (BM) cells was performed 12–59 months after ASCT in 60 consecutive women uniformly treated with six courses of FAC/FEC followed by HDCT and ASCT. With a median follow-up of 36 months after ASCT, there were no cases of MDS/AML among the 229 patients. In the …

OncologyAdultmedicine.medical_specialtyPathologyPopulationAneuploidyBreast NeoplasmsTransplantation AutologousBreast cancerAutologous stem-cell transplantationBone MarrowPredictive Value of Testshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsAdjuvant therapyMedicineHumanseducationCyclophosphamideEpirubicinNeoplasm StagingChromosome AberrationsTransplantationeducation.field_of_studyLeukemiabusiness.industryHematopoietic Stem Cell TransplantationMyeloid leukemiaNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyTransplantationPostmenopausemedicine.anatomical_structurePremenopauseChemotherapy AdjuvantDoxorubicinMyelodysplastic SyndromesFemaleBone marrowFluorouracilbusinessBone marrow transplantation
researchProduct

Proteomic Profile Study of Chronic Lymphocytic Leukemia-B Patients with IGVH and BCL6 Mutated or Unmutated Genes.

2004

Abstract Introduction: Chronic lymphocytic leukemia B (CLL-B) is the most frequent chronic lymphoproliferative disorder in western countries. The majority of patients are diagnosed in incipient Binet stage A. Some prognostic factors have been identified, as mutations in the genes coding for immunoglobulin variable regions (IgVH). Complementary somatic mutations in the BCL6 gene have been observed in 25% of CLL-B patients, although its clinical relevance remains unclear. Objective: To identify molecular markers of different patient groups of lymphoproliferative disorder through analysis of their proteomic profiles. Material and Methods: 15 samples of peripheral blood lymphocytes B from Binet…

NucleophosminProteomic ProfileProteomic ProfilingChronic lymphocytic leukemiaImmunologyCell BiologyHematologyBiologyBCL6medicine.diseaseBiochemistryMolecular biologyLymphocyte cytosolic protein 2hemic and lymphatic diseasesbiology.proteinmedicineAntibodyGeneBlood
researchProduct

Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR ass…

2013

Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center

AdultMaleAdolescentPcr assayCongenital cytomegalovirus infectionCytomegalovirusReal-Time Polymerase Chain ReactionSingle CenterHumansMedicineDna viralAgedMonitoring PhysiologicRetrospective StudiesTransplantationbusiness.industryAntiviral therapyvirus diseasesHematologyCmv dnaemiaAllo sctMiddle AgedAllograftsmedicine.diseaseVirologyReal-time polymerase chain reactionHematologic NeoplasmsCytomegalovirus InfectionsDNA ViralImmunologyFemalebusinessStem Cell TransplantationBone Marrow Transplantation
researchProduct

Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNγ CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia an…

2009

Rising levels of cytomegalovirus (CMV) DNAemia and/or pp65 antigenemia have been observed during pre-emptive ganciclovir therapy in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-SCT). We assessed the incidence of this event in our series, and investigated whether its occurrence was associated with an impairment in the CMV-specific T-cell response. A total of 36 allo-SCT recipients experienced one or more episodes of active CMV infection (n=68) that were pre-emptively treated with val(ganciclovir). Rising levels of antigenemia and DNAemia, and an isolated increase in antigenemia, were observed in 39.7 and 2.9% of all episodes, respectively. Receipt of corticost…

AdultCD4-Positive T-LymphocytesMaleGanciclovirAdolescentvirusesCongenital cytomegalovirus infectionCytomegalovirusCD8-Positive T-LymphocytesOpportunistic Infectionsmedicine.disease_causeHerpesviridaeImmediate-Early ProteinsViral Matrix ProteinsInterferon-gammaYoung AdultAntigenBetaherpesvirinaeDrug Resistance ViralmedicineHumansTransplantation HomologousAntigens ViralGanciclovirAgedTransplantationbiologybusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesHematologyMiddle AgedPhosphoproteinsbiology.organism_classificationmedicine.diseaseTransplantationsurgical procedures operativeCytomegalovirus InfectionsDNA ViralMutationImmunologyFemaleStem cellbusinessCD8medicine.drugBone Marrow Transplantation
researchProduct

Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC …

1998

Despite the wide use of G-CSF for mobilization of PBPC the best dose and schedule of G-CSF has not been definitively established. In this study we have compared three different schedules of G-CSF for mobilization of PBPC in normal donors including a single daily dose of 10 microg/kg/day for 5 days (21 donors) and doses of 6 (21 donors) or 8 microg/kg/12 h (6 donors) for 5 days. We demonstrate that G-CSF at doses of 6 and 8 microg/kg/12 h mobilizes significantly more CD34+ cells/ml of blood (83.3 +/- 6.7 and 121 +/- 6.9, respectively) than 10 microg/kg/day (71.6 +/- 6.5). Mobilization with 6 or 8 microg/kg/12 h of G-CSF was also associated with collection of significantly more CD34+ cells in…

AdultMaleAdolescentmedicine.medical_treatmentBlood volumeHematopoietic stem cell transplantationDrug Administration ScheduleAndrologyGranulocyte Colony-Stimulating FactorHumansTransplantation HomologousMedicinePlateletProgenitor cellChildAgedTransplantationMobilizationbusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell MobilizationBlood Cell CountGranulocyte colony-stimulating factorTransplantationmedicine.anatomical_structureImmunologyBlood Component RemovalFemaleBone marrowbusinessBone Marrow Transplantation
researchProduct

Detection of translocations affecting the BCL6 locus in B cell non-Hodgkin's lymphoma by interphase fluorescence in situ hybridization

2001

Structural alterations in 3q27 affecting the BCL6 locus are among the most frequent changes in B-NHL. The aim of the present study was to establish an interphase-FISH assay for the detection of all diverse BCL6 translocations in B-NHL. Two different approaches were tested, one using a PAC-clone spanning the major breakpoint region (MBR) of BCL6 (span-assay), and another using two BAC clones flanking the MBR (flank-assay). Interphase FISH with the span-assay detected the various BCL6 translocations in seven B-NHL cell lines. The dual-color flank-assay was evaluated in two laboratories independently: in normal controls, the cutoff level for false-positive signals was 2.6%, whereas the cutoff …

MaleCancer Researchmedicine.medical_specialtyLymphoma B-CellLymphomaMolecular Sequence DataTranslocationChromosomal translocationLocus (genetics)BiologyTranslocation GeneticFluorescenceChromosomesGeneticimmune system diseaseshemic and lymphatic diseasesmedicineHumansIn Situ Hybridization FluorescenceIn Situ HybridizationGeneticsGene Rearrangementmedicine.diagnostic_testBase SequenceBreakpointCytogeneticsB-CellBase Sequence; Chromosome Banding; Female; Gene Rearrangement; Humans; In Situ Hybridization Fluorescence; Karyotyping; Lymphoma B-Cell; Male; Molecular Sequence Data; Chromosomes Human Pair 3; Translocation GeneticHematologyGene rearrangementmedicine.diseaseMolecular biologyChromosome BandingOncologyChromosome 3KaryotypingPair 3FemaleChromosomes Human Pair 3TrisomyFluorescence in situ hybridizationHuman
researchProduct

Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transp…

1999

We have determined the effect of delayed addition of G-CSF after chemotherapy on PBPC mobilization in a group of 30 patients with high risk breast cancer (HRBC) undergoing standard chemotherapy followed by high-dose chemotherapy (HDCT) and autologous SCT. Patients received FAC chemotherapy every 21 days followed by G-CSF at doses of 5 microg/kg/day starting on day +15 (groups 1 and 2) or +8 (group 3) after chemotherapy. PBPC collections were performed daily starting after 4 doses of G-CSF and continued until more than 2.5 x 10(6) CD34+ cells had been collected. In group 1, steady-state BM progenitors were also harvested and used for SCT. Groups 2 and 3 received PBPC only. The median number …

AdultRiskmedicine.medical_specialtyAdolescentPlatelet Engraftmentmedicine.medical_treatmentCD34UrologyBreast NeoplasmsTransplantation AutologousBreast cancerAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorHumansMedicineProgenitor cellTransplantationChemotherapybusiness.industryHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseaseHematopoietic Stem Cell MobilizationSurgeryGranulocyte colony-stimulating factorTransplantationFemaleStem cellbusinessBone Marrow Transplantation
researchProduct